Financial Wire

Research Alert: Kmx: Adjusted Eps Well Ahead Of Consensus; New Ceo's Commentary Encouraging

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

CarMax, Inc. (KMX) posted Feb-Q adjusted EPS of $0.34 vs. $0.64 (-47%), well ahead of the $0.21 consensus. Adjusted EPS excluded $1.19/sh of net goodwill and restructuring charges, as reported EPS came in at -$0.85 vs. $0.58 in the year-ago quarter. The beat was due to a stronger-than-expected top line, as net sales fell 1.0% to $5.95B ($220M above consensus) and the gross margin contracted 90 bps to 10.2% (20 bps shy of consensus). Sales volumes were mixed, while pricing was weaker. While KMX's new CEO, Keith Barr, was appointed following the end of the quarter, we found his comments encouraging as he attempts to right the ship. Despite the beat, KMX shares are currently trading 5% lower in pre-market trading. We think the reaction reflects profit taking, as KMX shares had quietly posted a rebound of nearly 60% from the early November lows. We were encouraged by the quarter, as KMX's top and bottom lines exceeded expectations by a wide margin, although one-time items once again weighed on headline EPS.

相關文章

Mining & Metals

加拿大皇家銀行預計財產及意外保險業第一季業績將「保持韌性」。

加拿大皇家銀行資本市場預計財產及意外傷害保險(P&C)行業第一季業績將保持“韌性”,但認為這些業績不足以改變目前投資者對該行業的低迷情緒。 分析師巴特·迪亞爾斯基(Bart Dziarski)將Fairfax Financial (FFH.TO)的目標價從2234美元上調至2261美元,主要原因是Poseidon交易,並維持「跑贏大盤」評級。他認為,目前的估值並未反映Fairfax承保業務和投資組合的正面成長動能。 「我們預計,在有利(儘管增速放緩)的定價環境下,Fairfax的承保業績將保持強勁,而Fairfax歷來以善於把握機遇而著稱。Fairfax的投資組合已進行重新調整,以利用當前的利率環境推動投資業績改善,我們預計這一趨勢將持續下去。」他寫道。 Dziarski預計,隨著Fairfax持續保持穩健的經營業績,其市淨率估值相對於同業的折讓將會收窄。 對於多元化金融部門,Dziarski對goeasy (GSY.TO)仍持謹慎態度,並將關注goeasy在解決LendCare投資組合內部問題方面的最新進展,包括內部控制/財務報告以及核銷/貸款損失。 “我們認為,解決上述問題對於改善市場情緒至關重要。” 他維持對goeasy的「弱於大盤」評級,目標價為33.00美元。 Dziarski預計管理層的三點行動計劃要到2028年後才能生效,並認為隨著投資者重新評估賬面價值的可持續性以及公司穩定信貸表現的能力,其估值存在下行風險。Price: $2482.26, Change: $+25.42, Percent Change: +1.03%

$FFH.TO$GSY.TO
Australia

午盤漲幅最大的股票

Nektar Therapeutics (NKTR) 週一表示,其 rezpegaldesleukin 2b 期研究的 16 週擴展期數據顯示,重度至極重度斑禿患者的療效「進一步增強」。 Wedbush Securities 將 Nektar Therapeutics 的目標價從 70 美元上調至 95 美元,同時維持其「中性」評級。 Nektar 股價上漲 22%,盤中成交量接近 340 萬股,高於日均約 110 萬股。 美國總統川普週六簽署了一項行政命令,旨在加快嚴重精神疾病患者獲得治療的途徑。受此消息提振,Compass Pathways (CMPS)、GH Research (GHRS) 和其他迷幻藥公司的股價週一均有所上漲。 Compass Pathways 的股價飆升 49%,盤中交易量從日均約 305 萬股激增至超過 2,900 萬股。 GH Research 的股價上漲 14%,盤中交易量從日均約 19.2 萬股躍升至超過 95.37 萬股。Price: $103.50, Change: $+18.64, Percent Change: +21.97%

$CMPS$GHRS$NKTR
Sectors

產業動態:金融

週一下午,金融股漲跌互現,紐約證券交易所金融指數下跌0.1%,道富金融精選行業SPDR ETF(XLF)上漲0.2%。 費城房屋指數上漲0.4%,道富房地產精選產業SPDR ETF(XLRE)上漲0.2%。 比特幣(BTC-USD)上漲0.6%至75,663美元,10年期美國公債殖利率上升1個基點至4.25%。 公司新聞方面,Sila Realty Trust(SILA)同意被Blue Owl Capital(OWL)旗下房地產部門的關聯公司以全現金方式收購並私有化,交易金額約24億美元。 Sila股價飆漲19%,而Blue Owl股價下跌0.2%。

$OWL$SILA